Nutrigenetics and Dyslipidemia by Maryam Shalileh
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
3 
Nutrigenetics and Dyslipidemia  
Maryam Shalileh 
Islamic Azad University of Hamedan Branch 
Iran 
1. Introduction 
Dyslipidemia is an abnormal amount of lipids (abnormality in any of the lipoprotein 
fractions), especially elevated Low Density Lipoprotein (LDLs) and decreased High Density 
Lipoprotein (HDLs) in the blood (Shalileh et al., 2009). In developed countries, most 
dyslipidemias are hyperlipidemias; that is, an elevation of lipids in the blood, are often due 
to diet and lifestyle (Wikipedia., 2011; Shalileh et al., 2009). According to the Katharina 
studie’s, elevated cholesterol levels and dyslipoproteinemia are metabolic abnormalities that 
are becoming increasingly significant in industrialized countries, but also worldwide 
(Shalileh et al., 2009).  
There is a proportional increase in the risk of Coronary Heart Disease (CHD) with rising 
serum cholesterol levels (Shalileh et al., 2009). Dyslipidaemia is an important risk factor for 
Cardiovascular Disease (CVD) (Masson & McNeili., 2005).  
CVD is a common killer in both the Western and the developing world and is the leading 
cause of death globally (Lovegrove & Gitau., 2008).  
More people die annually from CVDs than from any other cause. An estimated 17. 1 
million people died from CVDs in 2004, representing 29%of all global deaths. Of these 
deaths, an estimated 7. 2 million were due to CHD and 5. 7 million were due to stroke. By 
2030, almost 23. 6 million people will die from CVDs, mainly from heart disease and 
stroke (WHO. 2011).  
Atherosclerosis is the most common cause of CHD and related mortality (Debra., 2008; 
Shalileh et al., 2009) .Endothelial dysfunction initiates atherosclerosis (Shalileh et al., 2009) .
The first observable event in the process of atherosclerosis is the accumulation of plaque 
(cholesterol from low-density lipoproteins, calcium, and fibrin) in the endothelium in large 
and medium arteries (Debra., 2008).  
One of the factors that causes endothelial dysfunction is dyslipidemia (Shalileh et al., 2009).  
2. Treatment 
CVD represents the paradigm of multi factorial disorders encompassing multiple genetic 
and non modifiable risk factors, for example older age and modifiable risk factors such as 
elevated total and LDL-cholesteroland and triglycerides concentrations, reduced HDL-
cholesterol concentrations (Ordovas & Corella., 2004; Ordovas., 2009; Perez-Martinez et al, 
2011; Lovegrove & Gitau, 2008). The interactions of those modulate plasma lipid 
concentrations and potentially CVD risk (Ordovas., 2009; Lovegrove & Gitau., 2008).  
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The link between serum cholesterol and the development of atherosclerosis was established 
a few decades ago and is now widely accepted. The National Cholesterol Education 
Program (NCEP) Adult Treatment Panel (ATP) publishes updated guidelines for treating 
lipid disorders. The latest version is the ATP III (Ordovas & Corella., 2004; Debra., 2008).  
The current recommendations aim to reduce the classical modifiable risk factors, and much 
emphasis has been placed on controlling high-plasma cholesterol levels (Ordovas & 
Corella., 004).  
Physicians are encouraged to refer patients to Registered Dietitians (RDs) to help patients 
meet goals for therapy (NCEP) based on LDL cholesterol levels. So the ATP III 
recommended the therapeutic lifestyle change (TLC) dietary pattern as the cornerstone for 
primary and secondary prevention of CHD. These guidelines consider dietary modification 
of treatment with emphasis on reducing the high saturated fat atherogenic diet and 
increased content of polyunsaturated fatty acid (PUFA) as well as controlling other 
behavioral factors. These therapies are used primarily to lower elevated blood levels of LDL-
C, raise HDL –C and lower triglycerides (TGs) (Rubin & Berglund., 2002; Debra., 2008; 
Ordovas & Orella., 2004).  
3. Response to the diet therapy 
Although dietary recommendations have been implemented to improve health and 
diminish the risk of CVD, type 2 diabetes and obesity, these recommendations have been 
established based on populations and not the individual. On the other hand the approach 
has been surprisingly unsuccessful in reducing CVD risk and the drastically different inter 
individual responses to a diet (Ordovas & Corella., 2004).  
So this clearly highlights the limitations of population-based nutritional recommendations 
and suggests that our understanding of the mechanisms responsible for inter-individual 
differences are far from being understood (Much et al., 2005).  
Recent clinical evidence suggests dramatic inter-individual differences and existence  
of consistent hypo- and hyperresponders in response of plasma lipids to dietary 
manipulations, ranging from reduced LDL-C levels and TGs in some, to decreased HDL-C 
levels to elevated TGs. So in some, a low-fat diet has caused a shift to a lipid pattern that is 
more atherogenic than the original one. This supports the hypothesis that responsiveness is 
related to genetic variation and existence of nutrient–gene interactions or personsۥ genotype 
(defined by the term ‘nutrigenetics’) (DeBusk, 2008; Perez-Martinez et al., 2011; Masson et 
al., 2003; Rideout., 2011; Ordovas et al., 2007).  
A classic example of this is the large variation in the concentration of serum low-density 
lipoprotein-cholesterol (LDL-C) in response to fish oil supplementation. The cardio 
protective effects of the fatty acids in fish oil, Eicosapentaenoic Acid (EPA) and 
Docosahexaenoic Acid (DHA) are well recognized. However, a potentially deleterious 
increase in LDL-C (5–10%) has been consistently reported after moderate to high doses of 
fish oil (>2 g day−1 EPA + DHA) (Lovegrove & Gitau., 2008).  
Despite this small, but significant increase in LDL-C, closer examination of the responses 
revealed a noticeable inter-individual variation. There was a mean increase in LDL-C of 4. 
1%, yet the spread of individual responses was substantial, with 33 of the 74 subjects 
demonstrating a lower serum LDL-C and the remaining 41 demonstrating a higher LDL-C 
(range −40 to +113%) following fish oil intervention. This heterogeneous response to a 
change in dietary fat, may be attributed to a number of factors; including age, gender, 
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baseline LDL-C levels, disease status and drug use. However, recent evidence strongly 
suggests that variations in a number of key genes may also be important (Lovegrove & 
Gitau., 2008). For example, individuals with specific of genetic variants in a gene may 
experience different type of lipoprotein changes when placed on a particular diet, whereas 
individuals with other variants in the gene may be resistant to the effects of the same diet. 
Although data is sparse in regard to whether such interactions exist, some limited work 
suggests that interactions may play an important role in determining lipoprotein profiles 
and may thus be informative for CVD risk prediction. For example, knowledge of a patient’s 
genetic information may allow medical providers and nutritional counselors to predict what 
lipoprotein changes are likely to occur if the patient starts a particular dietary intervention 
and, thus, better advise the patient regarding lifestyle changes (Musunuru., 2010; Ordovas & 
Corella., 2004).  
Lipoproteins are macromolecular complexes of lipids and proteins that originate mainly in 
the liver and intestine and are involved in transporting and redistributing lipids in the body. 
Lipid homeostasis is achieved by the coordinated action of numerous nuclear factors, 
enzymes, apolipoproteins, binding proteins, and receptors. Lipid metabolism is also 
linked with energy metabolism and is subject to many hormonal controls essential for 
adjusting to environmental and internal conditions. Genetic variability exists in humans 
for most of these components, and some of these mutations result in abnormal lipid 
metabolism and plasma lipoprotein profiles that may contribute to the pathogenesis of 
atherosclerosis. Many of these genes have been explored in terms of gene-diet interactions 
(Ordovas & Corella., 2004).  
So the shift towards personalized nutritional advice is a very attractive proposition, where, 
in principle, an individual can be given dietary advice specifically tailored to their genotype. 
However, the evidence-base for the impact of interactions between nutrients and fixed 
genetic variants on biomarkers of CVD risk is still very limited (Lovegrove & Gitau., 2008; 
Ordovas., 2006; Masson et al., 2003; Masson & Mc Neil., 2005; Fisler & Warden., 2005).  
With the advent of nutritional genomics, it's becoming clear that an individual's genetic 
makeup (genotype) is an important factor in this response and that dietary interventions 
must be matched to genotypes to effect the intended lipid-lowering responses (DeBusk., 
2008).  
A number of such genes have already been identified and include those involved with 
postprandial lipoprotein and triglyceride responses, homocysteine metabolism, 
hypertension, blood-clotting, and inflammation (Ordovas & Corella., 2004; DeBusk., 2008).  
Genetic polymorphism in human populations is part of the evolutionary process that results 
from the interaction between the environment and the human genome. Recent changes in 
diet have upset this equilibrium, potentially influencing the risk of most common 
morbidities such as cardiovascular diseases, diabetes, and cancer. Reduction of these 
conditions is a major public health concern, and such a reduction could be achieved by 
improving our ability to detect disease predisposition early in life and by providing more 
personalized behavioral recommendations for successful primary prevention. In terms of 
cardiovascular diseases, polymorphisms at multiple genes have been associated with 
differential effects in terms of lipid metabolism. The integration of genetic and 
environmental complexity into current and future research will drive the field toward the 
implementation of clinical tools aimed at providing dietary advice optimized for the 
individual's genome (Ordovas., 2009; Engler., 2009).  
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The recognition that nutrients have the ability to interact and modulate molecular 
mechanisms underlying an organism’s physiological functions has prompted a revolution in 
the field of nutrition (Much et al., 2005).  
For the field of nutrition, this would encompass the ongoing efforts to understand the 
relationships between the genome and diet, currently termed nutrigenomics and 
nutrigenetics (Much et al., 2005; Ommen., 2004) 
4. Nutritional genomics 
Nutrigenetics and nutrigenomics are promising multidisciplinary fields that focus on 
studying the interactions between nutritional factors, genetic factors and health outcomes. 
Their goal is to achieve more efficient individual dietary intervention strategies aimed at 
preventing disease, improving quality of life and achieving healthy aging (Ordovas., 2004).  
In contrast to most single gene disorders, chronic disorders (e. g., cardiovascular disease, 
cancer, diabetes) are far more complex. First, they involve multiple genes, each of which 
comes in more than one variation, that likely contribute in small ways to the overall 
condition rather than have the dramatic impact that is more typical with single gene 
disorders. Second, the genes are more likely to be influenced by environmental factors, 
which make the resulting phenotype murkier than with single-gene disorders. An 
individual might have gene variants that predispose to a particular chronic disorder but, 
depending on that individual's nutritional and other lifestyle choices, the disorder may or 
may not develop (DeBusk., 2008).  
Nutritional genomics or nutrigenomics is the newly developing field of science that focuses 
on the complex interaction among genes and environmental factors, specifically bioactive 
components in food and how a person’s diet interacts with his or her genotype to  
influence the balance between health and disease (DeBusk., 2009; Much et al., 2005; Fisler & 
Warden., 2005).  
Nutritional genomics is the umbrella term (Ryan-Harshman., 2008). There are two major 
subcategories of nutritional genomics: nutrigenetics and nutrigenomics (Much et al., 2005).  
The creation of nutrigenomics and nutrigenetics, two fields with distinct approaches to 
elucidate the interaction between diet and genes but with a common ultimate goal to 
optimize health through the personalization of diet, provide powerful approaches to 
unravel the complex relationship between nutritional molecules, genetic polymorphisms, 
and the biological system as a whole (Much et al., 2005).  
Thus, nutrition in the 21st century is poised to be an exciting and highly relevant field of 
research, as each new day is accompanied by advances in our understanding of how the 
interactions between lifestyle and genotype contribute to health and disease, taking us one 
step closer to achieving the highly desirable goal of personalized nutrition (Much et  
al., 2005).  
4.1 Nutrigenetics 
Nutrigenetics term was used first time by Dr R. O Brennan in 1975 (Farhud et al., 2010). 
Nutrigenetics is concerned with the effect of gene variations or gene variant or individual’s 
genetic make-up on the organism's functional ability, specifically its ability  
to digest, absorb, and use food (DeBusk., 2009; Ordovas & Corella., 2004; Lovegrove & 
Gitau., 2008). Nutrigenetics embodies the science of identifying and characterizing gene 
www.intechopen.com
 
Nutrigenetics and Dyslipidemia 
 
45 
variants associated with differential responses to nutrients or dietary pattern, functional 
food or supplement on a specific health outcome, and relating this variation to disease states 
(Much et al., 2005; Michael., 2008). The particular gene variants a person has to determine 
the nutritional requirements for that person and the gene-based differences in response to 
dietary components and developing nutraceuticals that are most compatible with health 
based on individual genetic makeup (DeBusk., 2009; Subbiah., 2007). Nutrigenetics will 
assist clinicians in identifying the optimal diet for a given individual, i. e., personalized 
nutrition (Much et al., 2005; Svacina., 2007; Zak & Slaby., 2007; Gillies., 2003).  
Furthermore, the concept is that if an individual is genotyped at various genes for disease-
associated risk alleles, a genotype-based diet or nutritional supplement regimen may be 
useful to overcome the genetic variation and reduce risk or prevent the disease altogether 
(Wood., 2008; Xacur-GarcAa et al., 2008; Kussmann & Fay., 2008).  
4.2 Nutrigenomics 
Nutrigenomics, is concerned with how bioactive components within food affect genes. The 
field of nutritional genomics is still evolving, and it is common to see "nutrigenomics" used 
as a shorthand version of "nutritional genomics ". However, keeping the concepts separate 
can be helpful when sorting out the underlying mechanisms involved (DeBusk., 2009). 
Nutrigenomics will unravel the optimal diet from within a series of nutritional alternatives, 
whereas nutrigenetics will help clinicians in identifying the optimal diet for a given 
individual, i. e., personalized nutrition (Much et al., 2005).  
Although these two concepts are intimately associated, they take a fundamentally different 
approach to understanding the relationship between genes and diet. Despite the immediate 
goals differing, the long-term goal of improving health and preventing disease with 
nutrition requires the amalgamation of both disciplines (Much et al., 2005)  
Nutrigenetics is the more familiar of the two subtypes of nutritional genomics (DeBusk., 
2009) At one end of the spectrum of nutritional genomics are the highly penetrant 
monogenic disorders that give rise to inborn errors of metabolism such as phenylketonuria 
(DeBusk., 2009). More recently less penetrant, more subtle variations have been identified 
that also affect the gene-encoded protein's function. However, such variations do not in 
themselves cause disease. Instead, they alter a person's susceptibility for developing a 
disease. Depending on the specific gene variant, the person's likelihood of developing a 
disorder may be increased or reduced. These genes are the primary focus of nutritional 
genomics, because they are common within the global population, they affect dietary 
recommendations about the types and amounts of food that best fit a person, and 
practical interventions are possible. These interventions can potentially improve the 
health potential of individual people and, by extrapolation, the populations in which they 
live (DeBusk., 2009).  
Current nutrition recommendations, directed towards populations, are based on estimated 
average nutrient requirements for a target population and intend to meet the needs of most 
individuals within that population. They also aim at preventing common diseases such as 
obesity, diabetes and cardiovascular disease. So diet has been reported as a major 
contributor to alarming prevalence of obesity (Shalileh et al, 2010). For infants with specific 
genetic polymorphisms, e. g. some inborn errors of metabolism such as phenylketonuria, 
adherence to current recommendations will cause disease symptoms and they need 
personalized nutrition recommendations (Hernell & West., 2008; Farhud & Shalileh., 2008).  
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Some other monogenic polymorphisms, e. g. adult hypolactasia, are common but with 
varying prevalence between ethnic groups and within populations. Ages at onset as well as 
the degree of the resulting lactose intolerance also vary, making population-based as well as 
personalized recommendations difficult. The tolerable intake is best set by each individual 
based on symptoms. For polygenetic diseases such as celiac disease, and allergic disease, 
current knowledge is insufficient to suggest personalized recommendations aiming at 
primary prevention for all high-risk infants, although it may be justified to provide such 
recommendations on an individual level should the parents ask for them.  
New technologies such as nutrigenetics and nutrigenomics are promising tools with which 
current nutrition recommendations can possibly be refined and the potential of 
individualized nutrition be explored. It seems likely that in the future it will be possible  
to offer more subgroups within a population personalized recommendations (hernell & 
West., 2008).  
The possibility of offering personalized nutritional advice to the individual is an attractive 
option for dietitians and nutrition scientists and is becoming practicable with the emergence 
of nutritional genomics. This developing field promises to revolutionize dietetic practice, 
with dietary advice prescribed according to an individual’s genetic makeup to prevent, 
mitigate or cure chronic disease (Lovegrove & Gitau., 2008). It has been also termed 
“personalized nutrition” or “individualized nutrition” (Ordovas & Corella., 2004; Perez-
Martinez et al., 2011). The practical applications of this research include a new set of tools 
that nutrition professionals can use to identify disease susceptibilities and a growing body 
of knowledge that will form the basis for developing strategies for disease prevention and 
intervention that are specifically targeted to the underlying genetic mechanisms (DeBusk., 
2008).  
Nutrigenetics and personalized nutrition are components of the concept that in the future 
genotyping will be used as a means of defining dietary recommendations to suit the 
individual. Over the last two decades there has been an explosion of research in this area, 
with often conflicting findings reported in the literature (Rimbach & Minihane., 2009).  
According to WHO reports, diet factors influence occurrence of more than 2/3 of diseases. 
Most of these factors belong to the categories of nutrigenetics and nutrigenomics. In the 
future both, nutrigenetics and nutrigenomics, will induce many changes in preventive 
medicine and also in clinical medicine (Svacina., 2007).  
Nutrients interact with the human genome to modulate molecular pathways that may 
become disrupted, resulting in an increased risk of developing various chronic diseases. 
Understanding how genetic variations influence nutrient digestion, absorption, transport, 
biotransformation, uptake and elimination will provide a more accurate measure of 
exposure to the bioactive food ingredients ingested. Furthermore, genetic polymorphisms in 
the targets of nutrient action such as receptors, enzymes or transporters could alter 
molecular pathways that influence the physiological response to dietary interventions. 
Knowledge of the genetic basis for the variability in response to these dietary factors should 
result in a more accurate measure of exposure of target tissues of interest to these 
compounds and their metabolites. Examples of how 'slow' and 'fast' metabolizers respond 
differently to the same dietary exposures will be discussed. Identifying relevant diet-gene 
interactions will benefit individuals seeking personalized dietary advice as well as improve 
public health recommendations by providing sound scientific evidence linking diet and 
health (EL-Sohemy, 2007; Amouyel., 2000).  
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A really personalized diet will be a diet considering the nutritional status, the nutritional 
needs based on age, body composition, work and physical activities, but also considering 
the genotype. That is, define the "nutritional phenotype (Perez-Martinez et al., 2011; 
Miggiano   & De Sanctis., 2006). It is clear that integrating knowledge of gene variants into 
dietary recommendations for populations and individuals will increasingly play a role in 
nutrition counseling and policy making (DeBusk., 2008).  
Nutrigenetics will provide the basis for personalized dietary recommendations based on the 
individual's genetic makeup. This approach has been used for decades for certain single 
gene diseases; such as phenylketonuria, however, the challenge is to implement a similar 
concept for common multi factorial disorders and to develop tools to detect genetic 
predisposition and to prevent common disorders decades before their manifestation. The 
preliminary results involving gene-diet interactions for cardiovascular diseases and cancer 
are promising, but mostly inconclusive. Success in this area will require the integration of 
different disciplines and investigators working on large population studies designed to 
adequately investigate gene-environment interactions (Ordovas & Corella., 2004; Ordovas & 
Mooser., 2004).  
4.3 Nutritional genomics and lipid metabolism 
From a health perspective, the major concerns regarding genes and lipid metabolism center 
on susceptibility to vascular disease. Genes involved with cholesterol homeostasis offer 
examples of how genetic variations affect lipid metabolism and, thereby, disease risk 
(DeBusk., 2009).  
The blood lipid response to diet is influenced by polymorphisms within genes for the 
apolipoproteins as well as within those for enzymes, such as hepatic lipase, that are 
involved in lipid metabolism (fisler & Warden., 2005).  
The major focus of nutritional genomics research is on identifying (1) gene-disease 
associations, (2) the dietary components that influence these associations, (3) the 
mechanisms by which dietary components exert their effects, and (4) the genotypes that 
benefit most from particular dietary choices (DeBusk., 2008).  
The following section takes a brief look at some of the key diet-related genes and their 
known variants and how these variants affect the person's response to diet. Keep in mind 
that chronic diseases involve complex interactions among genes and bioactive food 
components, and unraveling the details will require population and intervention studies 
large enough to have the statistical power needed to draw meaningful conclusions. 
Although what is known today is but the tip of the iceberg compared to what will come in 
the years ahead (DeBusk., 2008).  
Over the last two decades there has been an explosion of research in this area, with often 
conflicting findings reported in the literature (Rimbach & Minihan., 2009).  
5. Candidate gene approach 
The candidate gene approach involves the selection and study of biologically relevant genes. 
Genetic polymorphisms in these genes, known as Single-Nucleotide Polymorphism (SNPs), 
can alter susceptibility to a disease. Candidate or "susceptibility" genes should meet one or 
more of the following conditions: genes that are chronically activated during a disease state 
and have been previously demonstrated to be sensitive to dietary intervention; genes with 
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functionally important variations; genes that have an important hierarchical role in 
biological cascades; polymorphisms that are highly prevalent in the population (usually 
>10% for public health relevance); and/or genes with associated biomarkers, rendering 
clinical trials useful (Lovegrove & Gitau., 2008).  
Many studies have investigated this possibility and have largely focused on genes whose 
products affect lipoprotein metabolism, eg, apolipoproteins, enzymes, and receptors. 
Although there have been several reviews of such studies, many of them may have led to 
articles being omitted and introduced bias toward positive findings (Ordovas., 2006).  
5.1 Apolipoprotein A-I (Apo AI)  
The Apo AI gene, codes for apolipoprotein A-I, is a major structural and functional 
component of HDL constituting about 70% to 80% of HDL protein mass, and is the main 
activator of the enzyme lecithin cholesterol acyl transferase (LCAT) (Ordovas & Corella., 
2004; Lovegrove & Gitau., 2008; Much et al., 2005; DeBusk., 2008).  
Plasma HDL-cholesterol plays a protective role for CVD (Lovegrove & Gitau., 2008; Much et 
al., 2005). Its gene product Apo A-I plays a central role in lipid metabolism and CVD risk. 
Pedigree studies have reported associations between genetic variation at the Apo A1 locus 
and plasma lipid and lipoprotein levels (Ordovas & Corella., 2004). One of the variants that 
has been identified to be diet-related is -75G>A, in which the typical guanine has been 
replaced with an adenine at position 75 within the regulatory region of the Apo A-I gene 
(DeBusk., 2008).  
It was reported that this polymorphism was associated with Apo A-I and HDL-C 
concentrations, and individuals carrying the A-allele presented with the highest levels, 
compared with subjects homozygotes for the G allele (G/G) but many studies have had 
contradictory results (Lovegrove & Gitau., 2008; Ordovas & Corella., 2004).  
In the context of the Framingham Heart Study, individuals with a polymorphism in the Apo 
A1 gene promoter region (–75 G/A) were found to respond differently to dietary PUFA 
(Much et al., 2005; Lovegrove & Gitau., 2008).  
The inconsistencies in reported studies outcomes are not necessarily a result of inherent 
differences, but are a result of a nutrient–gene interaction, i. e. a classic example of where 
individualized dietary advice could be important in relation to exerting a positive influence 
on HDL-C levels and CVD risk (Lovegrove & Gitau., 2008; Much et al., 2005). In brief, that 
individuals with the A allele showed an increase in HDL levels following an increased 
consumption of PUFA. In contrast, those with the more common G allele showed an inverse 
relationship between HDL levels and PUFA consumption. This study revealed that 
differences in sex also mediate the response. Indeed, men did not show a relationship 
between HDL and PUFA consumption, irrespective of their Apo A1 polymorphism 
(Lovegrove & Gitau., 2008; Much et al., 2005).  
A common practice in treating dyslipidemia is to reduce the saturated fat content of the diet 
and increase the polyunsaturated fat content. Typically, HDL levels fall in women with the 
more common G allele as the polyunsaturated content of the diet increases, an effect counter 
to the desired one. These women would benefit from a fat modified diet that keeps amounts 
of both saturated and polyunsaturated fat low and increases amounts of monounsaturated 
fat. Women with the A allele, increasing polyunsaturated dietary fat leads to increased HDL 
levels, and the effect is "dose-dependent; so in women with the more common G allele, 
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increasing dietary Polyunsaturated Fat (PUFA) levels from less than 4% of total energy to 
4% to 8% to greater than 8% resulted in a corresponding decline in HDL levels as PUFA 
levels increase. However, in women with the A allele, increasing PUFA concentrations (>8% 
of energy derived from PUFA) increased HDL levels and the increase is more dramatic in 
the presence of two copies of the A alleles than it is with just one. For these women, a diet 
low in saturated fat, moderate in polyunsaturated fat (8% or greater of total calories), and 
supplying the rest in monounsaturated fat has the greatest benefit in raising HDL levels. 
Clearly, whether a person has the -75G>A Apo AI variant, and how many copies are 
present, will affect any therapeutic intervention developed to correct dyslipidemia (DeBusk., 
2009; Much et al., 2005; Debra., 2008).  
Juo et al (Hank Juo., 1999) used a meta analysis approach to show the lack of consistency 
between the less common A-allele and higher HDL-cholesterol concentrations. In view of 
the significant gene-diet interaction observed for those intervention studies, they 
examined whether these results could be extrapolated to a free living population, 
consisting of about 1600 Framingham Offspring Study participants (Ordovas et al., 2002). 
The results from the straightforward association between genotype and phenotype were 
disappointing and suggested that the G/A polymorphism was not associated with HDL- 
cholesterol, Apo A-I concentrations, nor with any other anthropometrical or plasma lipid 
variable examined. To examine the potential modifying effect of dietary fat on these 
associations, they fitted multivariate linear regression models, including interaction terms 
for fat intake [total, Saturated Fatty Acid (SFA), Monounsaturated Fat (MUFA), and PUFA 
fat]. No significant interactions were observed between the G/A polymorphism, total, 
SFA, and MUFA fat intakes. However, in women, HDL-cholesterol concentrations were 
associated with a significant interaction between PUFA intake and Apo A1 genotype  
 (p = 0. 005). Using PUFA as a dichotomous variable, their data show that G/G women 
consuming <6% PUFA/day had higher HDL-cholesterol (1. 48 ± 0. 40 m mol/L) than A-
carriers (1. 43 ± 0. 40 m mol/L). Conversely, when consuming ≥6% PUFA/day, G/G had 
lower HDL-cholesterol concentrations (1. 44 ± 0. 39 m mol/L) than A-carriers (1. 49 ± 0. 39 
m mol/L). In men, the situation was more complex because the effects were observed 
using three-way interactions, including smoking and alcohol consumption, in the 
analyzes (Ordovas & Corella., 2004).  
The most evident application of these results may be to help us make more efficacious 
dietary recommendations based on genetic profile. It is clear that subjects with the A-allele 
at this Apo A1–75 (G/A) polymorphism will benefit from diets containing a high percentage 
(it is important to underscore that we are talking about percent in the diet and not about 
total amounts) of PUFA (i. e., vegetable oils, fish, nuts, and so on). According to their data, 
this should result in higher HDL-cholesterol concentrations, which in turn should lower 
CVD risk. These findings suggest that the expression of the Apo A1 gene may be regulated 
by PUFA (Ordovas & Corella., 2004).  
On the other hand, of 13 reports, 5 found that the presence of the Apo A-I–75 (G/A) A allele 
instead of the common G allele resulted in greater LDL-cholesterol responses to changes in 
dietary. In addition, significant interactions between the G/A genotype and diet were found 
for changes in total and LDL cholesterol when subjects changed from a low-fat diet to a diet 
high in MUFAs. No significant interactions between diet and other polymorphisms in the 
Apo A-I gene were shown (Ordovas & Corella., 2004).  
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5.2 Apolipoprotein A-IV (APOA4) 
Apo A-IV is a 46-Kd plasma glycoprotein that is synthesized by intestinal enterocytes 
during lipid absorption and is incorporated into nascent chylomicrons. Apo A-IV enters 
circulation on lymph chylomicrons, but then dissociates from their surface and circulates 
primarily as a lipid-free protein. Several genetically determined isoforms of Apo A-IV have 
been detected; amino acid positions 360 and 347 of the mature protein are the most 
common. The polymorphism at position 360 is due to a CAG → CAT substitution at codon 
360 in the Apo A4 gene and encodes a Q360H (Gln → His) substitution in the carboxyl 
terminus, and produces an isoform, originally known as Apo A-IV-2, one charge unit more 
basic than the common isoform, Apo A-IV-. In some population studies the Apo A-IV-2 
allele is associated with higher levels of HDL-cholesterol and or Apo A-I and/or lower 
triglyceride (TG) levels, as well as lower LDL-cholesterol, lower Lp (a), and higher fasting 
glucose and insulin levels, but no associations have been observed in other studies (Ordovas 
& Corella., 2004).  
The other common mutation (Thr347→Ser) is due to an ACT→TCT substitution at codon 
347 in the human Apo A-IV gene, it is found within subjects with the apoA-IV-1 isoform. 
Several population studies note that carriers of the 347S allele have lower plasma, total, 
LDL-cholesterol, Apo B levels, and Lp (a) levels, than 347T/T homozygotes. The results of 
many reports showing that male carriers of the less common allele at the Gln360His 
polymorphism were less responsive to changes in dietary fat and cholesterol or cholesterol 
alone (Ordovas & Corella., 2004).  
Several studies have focused on the interaction between the Apo A4 locus and dietary 
factors, both in the fasting and postprandial states. Similar to the findings for other genes, 
the data are conflicting when it comes to the effect of Apo A-IV polymorphisms on the LDL 
response to dietary cholesterol. However, according to Weinberg (Weinberg., 2002), the 
results from different studies can be partially reconciled if one assumes that the dietary fatty 
acid effects dominate over the allele effects. Therefore, if dietary cholesterol intake is the 
principal variable, and total fat intake is moderate and constant, Q/H subjects display an 
attenuated response of LDL-cholesterol. However, when dietary cholesterol intake is 
changed in the setting of a higher baseline dietary fat intake or with a change in fat 
saturation, the fatty acid effects on LDL levels predominate and overrule the allele effect. 
The impact of the Q360H polymorphism on cholesterol absorption may be greater on a high 
PUFAs intake. However, dietary PUFA counteract the effect of dietary cholesterol on the 
expression of hepatic LDL receptors. Thus, the final effect of Apo AIV alleles on the LDL 
response to dietary cholesterol may be determined by the relative amounts of cholesterol, 
saturated fatty acids (SAFAs), and PUFAs in the diet (winberg et al., 2000; Weggemans., 
2000; Lopez-Miranda., 1998; Ordovas & Corella., 2004; Hockey., 2001).  
There is more consistency and probably less complexity regarding the impact of Apo A-IV 
polymorphisms on HDL-cholesterol: When total fat intake is raised or lowered, Q/H 
subjects have an exaggerated, and Threonine /Serine (T/S) subjects an attenuated, response 
in plasma HDL levels. It has been suggested, and Weinberg demonstrated, that a high-
PUFA intake may amplify this effect (Ordovas & Corella., 2004; Winberg et al., 2000).  
Given the relationships between plasma TG and plasma HDL-cholesterol levels, it is 
possible that the response of plasma HDL-cholesterol levels to changes in dietary fat is 
mediated by Apo A-IV allele effects on postprandial triglyceride-rich lipoprotein 
metabolism. These studies clearly illustrate the extreme complexity associated with the 
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interpretation of results from studies involving gene-diet interactions (Ordovas & Corella., 
2004).  
The presence of serine instead of threonine at position 347 in the Apo A-IV gene was 
associated with increased total and LDL-cholesterol responsiveness when subjects switched 
from a high-SFA diet to a National Cholesterol Education Program Step I diet. When the 
same subjects changed from the National Cholesterol Education Program Step I diet to a 
high-MUFA diet, subjects with the Thr /Thr genotype had a 1% decrease in total cholesterol 
concentrations, whereas subjects with the Ser allele had a 5% increase in total cholesterol 
concentrations. When the Thr347Ser and the Apo A-I–75 (G/A) genotypes were combined, 
carriers of the A and Ser alleles showed greater LDL-cholesterol responses to changes in 
dietary fat. However, Carmena-Ramon et al (Carmena-Ramon et al., 1998) investigated both 
the Gln360His and Thr347Ser polymorphisms and found no gene-diet or haplotype-diet 
interactions (Masson et al., 2003). The evidence that exists for an interaction between diet 
and the Apo A-IV glutamine-histidine mutation at position 360 (Gln360His) suggests that 
Gln / Gln subjects show significantly greater total and LDL-cholesterol responses and that 
Gln /His subjects show greater HDL-cholesterol responses to changes in dietary fat, 
cholesterol, or both. Although Wallace et al found no significant differences in LDL-
cholesterol responses between genotypes, dense LDL cholesterol decreased more in subjects 
carrying the His allele when polyunsaturated fatty acids (PUFAs) replaced SFAs in the diet 
(Wallace et al, 2000). In the same study, there was a significant difference in HDL-cholesterol 
responses between genotype groups such that concentrations decreased in Gln /Gln subjects 
and increased in Gln /His subjects (Masson et al., 2003).  
5.3 Apolipoprotein B (Apo B)  
Apolipoprotein B is the main protein component of low-density-lipoprotein (LDL) and 
contains several domains. The human Apo B is 43 kb in length with 81 bp signal sequence. 
Numerous polymorphisms have been identified on this gene (Heilbronn et al., 2000).  
The evidence for an interaction between the XbaI polymorphism and diet is inconsistent. In 
2 studies, X-X- subjects showed greater LDL-cholesterol responses, whereas Tikkanen et al, 
found that subjects carrying the X+ allele had greater total, LDL-, and HDL-cholesterol 
responses. However in, analysis of these data, the XbaI polymorphism only explained a 
significant proportion of variance of the change in HDL cholesterol (Tikkanen et al., 1995). 
In one research they found no significant effect on LDL-cholesterol responsiveness, although 
X-X-subjects showed the greatest HDL2- and VLDL-cholesterol responses. Finally, in 
another study researchers studied the effect of the XbaI polymorphism in subjects with the 
common Apo E3/3 genotype and found that X-X- subjects showed the greatest 
triacylglycerol response. Rantala et al conducted a meta-analysis of all published dietary 
trials. In their analysis of 8 studies, X-X+ subjects had greater LDL responses than did X+X+ 
subjects and no significant differences in the responses of total or HDL cholesterol or 
triacylglycerol were found between genotypes (Masson et al., 2003; Rantala., 2000). Two of 7 
intervention studies found that the EcoRI R- allele was associated with significantly greater 
total and LDL-cholesterol responses to changes in dietary fat and cholesterol. Only one 
study found an interaction between the MspI polymorphism and response to diet. Ten 
intervention studies found no significant effects of the Apo B signal peptide 
insertion/deletion (I/D) polymorphism on dietary responsiveness; however, 2 studies 
reported a significantly greater responsiveness in subjects homozygous for the I allele. In a 
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study, 43 men and women were observed to compare the effects of insoluble and soluble 
fiber on plasma lipids. Their statistical model identified gene-diet interactions. However, 
they did not look specifically at differences between genotype groups. It was found that D/D 
subjects had similar decreases in HDL cholesterol after consumption of the insoluble- and 
soluble-fiber diets. However, I/I subjects had larger HDL-cholesterol decreases with the 
soluble-fiber diet, whereas I/D subjects had larger HDL-cholesterol decreases with the 
insoluble-fiber diet. The gene-diet interaction was significant (P = 0. 021) (Masson et al., 
2003; Rantala., 2000).  
In response, low-fat, low-cholesterol diet, I/I subjects showed the greatest decrease in HDL2. 
In addition, I/I and I/D subjects showed increased VLDL-cholesterol and decreased LDL-
cholesterol concentrations, whereas D/D subjects showed decreased VLDL-cholesterol and 
increased LDL-cholesterol concentrations. The I/D polymorphism showed no significant 
effect on the responsiveness of total, LDL, or HDL cholesterol or triacylglycerol in a meta-
analysis of 7 studies (Masson et al., 2003).  
5.4 Apolipoprotein E (APO E) 
Apo E gene variants have implications for nutrition therapy related to preventing and 
treating CVD and the responses to dietary fat, soluble fiber, and alcohol. The impact of Apo 
E genotype on individual variability in its LDL cholesterol response to diet interventions 
and CVD risk has been extensively investigated over the past 30 years. Apo E contains 299 
amino acids, considering Apo E’s key role in lipoprotein metabolism, being involved in 
chylomicron metabolism, very low-density lipoprotein synthesis and secretion, and in the 
cellular removal of lipoprotein remnants from the circulation. Apo E serves as a ligand for 
multiple lipoprotein receptors. This gene locus is polymorphic, with 84 gene variants being 
characterized to date. The prevalence of this SNP varies in different populations (Lovegrove 
& Gitau., 2008; Rubin & Berglund., 2002; Ordovas & Corella., 2004; DeBusk., 2009).  
Apo E is present in a subfraction of lipoprotein (a). The receptor-binding properties reside in 
the N-terminal part of Apo E, whereas the lipid-binding domain resides in the C-terminal 
portion. It was recognized that Apo E was present as three different Apo E isoforms (E2, E3, 
and E4), coded by three different alleles (e2, e3, and e4), resulting in six homo and 
heterozygous genotypes (e2/e2, e2/e3, e2/e4, e3/e3, e3/e4, e4/e4). Apo E2 differs from the 
wild type, Apo E3, by a substitution of arginine for cysteine at amino acid 158, and Apo E4 
differs from Apo E3 by a substitution of cysteine for arginine at amino acid 112. In addition, 
several other genetic variants have been described at the Apo E locus (Rubin & Berglund., 
2002; Lovegrove & Gitau., 2008; Masson et al., 2003; Farhud et al., 2010).  
Persons with E4 variant respond to a high-fat diet negatively with an increased risk for 
coronary heart disease (CHD). In these individuals, low-fat diet should be useful (Farhud et 
al., 2010; Sheweta et al., 2011).  
Population studies show that plasma cholesterol, LDL cholesterol, and Apo B levels are 
highest in subjects carrying the Apo E4, intermediate in those with the Apo E3, and lowest 
in those with the Apo E2 isoform. An initial observation was that the association of the  
Apo E4 isoform with elevated serum cholesterol levels was greater in populations 
consuming diets rich in saturated fat and cholesterol than in other populations (Ordovas & 
Corella., 2004).  
Corella and Ordovas reviewed the numerous studies that have investigated the diet-gene 
interaction for Apo E variants. People with at least one E4 allele have the highest basal levels 
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of various lipids and show the greatest lipid-lowering response to a low-fat diet. Taking into 
account which Apo E alleles a person has is helpful in developing diet and lifestyle 
interventions for improving serum lipid levels (DeBusk., 2009).  
In 46 studies that examined the Apo E locus and alterations in dietary fat content, 
significantly different responses in total and LDL cholesterol by Apo E genotype were 
reported in 8 and 11 studies, respectively, with the Apo E4 individuals generally being the 
most responsive (Lovegrove & Gitau., 2008; Masson et al., 2003).  
Note that despite the numerous studies examining the relation between Apo E genetic 
variability and LDL-cholesterol response to diet intervention, there is considerable 
inconsistency regarding the magnitude and significance of the reported associations, and 
this locus continues to be the subject of intense research (Ordovas & Corella., 2004).  
In a study, there are 29 intervention studies that examine Apo E-diet interactions. A total of 
3224 subjects participated in these studies, ranging from 16 to 420 subjects per study. Of the 
29 studies, 12 demonstrated no significant Apo E-diet interactions, 15 reported significant 
interactions (E4 was usually associated with increased dietary response), and 2 were 
undefined. Using the same available literature, but different selection criteria, Masson, 
reviewed 62 dietary intervention periods, including 3223 subject-by-diet interventions 
(Masson et al., 2003). Again, the range of the studies varied between 8 and 210 subjects per 
dietary intervention. According to this review, 42 of the diet interventions did not 
demonstrate significant Apo E-diet interactions, and only 19 provided evidence for 
significant interactions, clearly demonstrating the diversity of the results presented in the 
original papers as well as those obtained from review papers (Ordovas & Corella., 2004; 
Masson et al., 2003).  
The heterogeneous response to changes in dietary fat may be attributed to a number of 
factors including age, gender, baseline LDL-C levels, disease status and drug use 
(Lovegrove & Gitau., 2008).  
One difference between the negative studies and those reporting significant Apo E  
gene–diet interactions relates to the baseline lipid levels of the subjects. Studies  
reporting significant associations often included subjects who were moderately 
hypercholesterolemic and/or had significant differences in base total cholesterol and 
LDL-cholesterol among the Apo E genotype groups. This suggests that the significant 
gene-diet interaction is apparent only in subjects susceptible to hypercholesterolemia. 
Concerning differences in dietary interventions, there were significant interactions in 
studies in which total dietary fat and cholesterol were modified. Several mechanisms are 
proposed to explain these Apo E-related differences in individual response to dietary 
therapy. Some studies show that intestinal cholesterol absorption is related to Apo E 
phenotype, with Apo E4 carriers absorbing more cholesterol than non-Apo E4 carriers. 
Other mechanisms such as different distribution of Apo E on the lipoprotein fractions, 
LDL Apo B production, bile acid, and cholesterol synthesis, and postprandial lipoprotein 
clearance may also be involved (Ordovas & Corella., 2004).  
On the other hand although the obvious dietary factors implicated in gene-diet interactions 
affecting plasma lipid levels are dietary fats and cholesterol, other dietary components have 
revealed significant interactions. This is the case for alcohol intake.  
Although the raising effect of alcohol consumption on high-density lipoprotein (HDL)-
cholesterol levels is well established, the effect on LDL-cholesterol is still unclear. It is 
possible that the reported variability will be due to interactions between genetic factors and 
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alcohol consumption. Using cross-sectional analysis, researcher examined whether variation 
at the Apo E locus modulates the association between alcohol consumption and LDL-
cholesterol levels in a healthy population based sample of 1014 male and 1133 female 
participants in the Framingham Offspring Study (Corella et al., 2001). In male nondrinkers, 
LDL-cholesterol levels were not different across Apo E groups; however, in male drinkers, 
there were differences in LDL-cholesterol, with Apo E2 subjects displaying the lowest levels. 
When LDL cholesterol levels were compared among the Apo E subgroups by drinking 
status, LDL-cholesterol levels in Apo E2 male drinkers were lower than in Apo E2 non 
drinkers. Conversely, in Apo E4 males, LDL-cholesterol was higher in drinkers than in 
nondrinkers. This Apo E-alcohol interaction remained significant after controlling for age, 
BMI, smoking, fat, and energy intake. In women, the expected effect of Apo E alleles on 
LDL-cholesterol levels was present in both drinkers and nondrinkers. Multiple linear 
regression models showed a negative association between alcohol and LDL-cholesterol 
levels in Apo E2 men, with alcohol intake a continuous variable. Conversely, in Apo E4 
men, this association was positive. There were no statistically significant associations in 
either Apo E3 men or in women. These data suggest that in men, variability at the Apo E 
locus partially modulates the effects of consuming alcoholic beverages on LDL-cholesterol 
levels (Ordovas & Corella., 2004).  
The effect of alcohol was also investigated in the Copenhagen City Heart Study (Frikke-
Schmidt., 2000). In that study, there was an interaction between alcohol and Apo E among 
women, in which higher triglyceride levels were associated with both the E2 and E4 alleles 
among women who regularly consumed alcohol. For men, increased triglyceride levels 
among E2 and E4 carriers were seen across the entire alcohol distribution spectrum, perhaps 
because of some degree of alcohol consumption among all men. Overall, the results 
suggested that metabolic stresses, such as the postprandial situation or alcohol 
consumption, might contribute to uncover underlying differences between Apo E genotypes 
in cholesterol, triglyceride or lipoprotein metabolism (Frikke-Schmidt., 2000).  
The effect of the Apo E gene on lipoproteins may differ with age. In elderly individuals as 
well as in children, there is less difference in LDL cholesterol levels in individuals carrying 
the E4 allele versus non-E4 carriers. Interestingly, in both of these age groups, the presence 
of the Apo E2 allele was associated with lower LDL cholesterol levels. An age-dependent 
variation between Apo E and plasma lipids was also seen by Jarvik et al (Jarvik et al, 1997). 
By longitudinally following male Caucasian twins, the authors demonstrated that whereas 
E4 carriers initially had higher triglyceride and cholesterol levels compared with E3 
homozygotes, this difference disappeared over an 18-year period (Rubin & Berglund., 2002).  
A sex-specific association between Apo E2 and HDL cholesterol levels has been described in 
Turkish individuals. In Turkish women, but not men, the frequency of the Apo E2 allele 
increased almost six fold from the lowest to the highest HDL cholesterol tertiary (Rubin & 
Berglund., 2002). The available information show, significant diet–Apo E gene interactions 
occurred in male-only studies. In studies including men and women, significant effects were 
noted only in men, suggesting a significant gene-sex interaction (Ordovas & Corella., 2004).  
As pointed out above, in studies in which an Apo E gene nutrient interaction was found, it 
was generally more common among men than women, suggesting a modulation by sex. 
Interestingly, in the study by Mahley et al, on HDL levels in Turkish individuals, the 
authors suggested that the association of Apo E2 with higher HDL cholesterol levels found 
in women but not in men may be caused by a sex difference in hepatic lipase. Among 
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women, a lower hepatic lipase activity might allow the detection of the modulating effect of 
Apo E genotypes, whereas this effect might be overwhelmed by a higher enzyme activity in 
men (Mahley et al., 2000). This is an analogous situation to the suggestion above that 
differences in susceptibility might be uncovered by a metabolic challenge (Rubin & 
Berglund., 2002).  
Other causes for the observed differences between studies may be the presence of 
confounders, the type of dietary intervention used, the population studied and, importantly, 
the number of subjects in the respective studies. A small number of subjects limits the 
possibility of detecting differences, or could alternatively lead to spurious associations. 
Although the number of studies addressing the gene nutrient interaction for Apo E is 
growing, in most studies so far this has been a secondary endpoint, usually analyzed post 
hoc. Perhaps the most likely possibility is that a number of dietary interventions will elicit 
variable responses across Apo E genotypes, but that the ability to detect such differences 
will depend on the strength and type of intervention as well as on specific recipient factors 
(type of population, presence of hyperlipidemia, etc. ). In the end, however, our ability  
to confirm or refute the presence of Apo E gene nutrient interactions as well as to 
understand their metabolic basis fully will require larger and more detailed studies (Rubin 
& Berglund., 2002).  
Inconsistency in nutrient–gene interactions in relation to Apo E polymorphisms may be a 
result, in part, of retrospective genotyping of small study cohorts, for which the genotype–
diet–LDL-C interactions were not the primary outcome. This factor has resulted in the 
under-representation of the less-frequent genotypes and, although trends may have been 
evident, many of the studies were clearly under-powered to detect significant genotype–
treatment effects. The prospective genotyping of larger study cohorts has been used as an 
alternative approach to increase statistical power (Lovegrove & Gitau., 2008).  
 However, recent evidence strongly suggests that variations in a number of key genes may 
also be important, including common variants of the Apo E gene. The most convincing 
evidence to date for genotypic effects on dietary response comes from the extensively 
studied Apo E gene variant (Lovegrove & Gitau., 2008).  
A metaanalysis has been published recently that summarizes the overall findings from 
studies using a variety of end-point measures. A mean 40–50% increase in CHD risk was 
observed in E4 carriers (overall OR 1. 42) relative to the wild-type E3/E3 genotype, with no 
apparent differences for either the E2 and E3 subgroups (OR 0. 98). Although a causal 
mechanism to link E4 with increased CHD risk has not been fully elucidated, the association 
has been ascribed to a higher concentration of LDL-C. This higher LDL-C is believed to arise 
from the Apo E4 isoform having a relatively higher affinity for its membrane 
(LDL/chylomicron remnant) receptor and feedback inhibition of receptor activity in E4 
carriers Other mechanisms relating to reduced antioxidant status may also be operative 
(Lovegrove & Gitau., 2008).  
There is the large variation that is observed in the concentration of serum LDL-cholesterol 
(LDL-C) in response to fish oil supplementation. The cardioprotective effects of the fatty 
acids in fish oil include eicosapantanoiec acid (EPA) and docosahesanoiec acid (DHA) are 
well recognized. However, a potentially deleterious increase in LDL-C (5–10%) has been 
consistently reported after moderate to high doses of fish oil (>2 g EPA+ DHA/d). These 
data showed the DHA rather than the EPA in fish oils that is responsible for the LDL-C 
raising effects in E4 individuals (Lovegrove & Gitau., 2008).  
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In contrast, those with one or more E4 alleles have the highest serum total cholesterol, LDL-, 
and Apo B levels, the lowest HDL-C levels, and have elevated fasting and postprandial 
triglyceride levels. They respond best to a low-fat diet but are the least responsive to soluble 
fiber for lowering serum lipids or to exercise for increasing HDL levels. Fish oil 
supplementation in these people increases total cholesterol and reduces HDL. Whether a 
person has the U allele or the E4 allele appears to make a difference in the diet and lifestyle 
recommendations that would be appropriate for improving vascular health (DeBusk., 2009).  
Two prospectively genotyped studies designed to test the hypothesis that Apo E 
polymorphism has a significant effect on the LDL-C response to EPA and DHA have 
recently been completed (Lovegrove & Gitau., 2008).  
Overall, the triglyceride response to the fat load was lower during fish oil supplementation, 
and interestingly the decrease in the incremental area under the curve for triglyceride levels 
was significantly higher for E2 carriers compared with E3 homozygotes and E4 carriers 
(Rubin & Berglund., 2002).  
Although a number of previous studies have observed effects of Apo E genotype in 
response to dietary total fat and saturated fatty acid (SFA) manipulation, only one study to 
date has examined the Apo E genotype–dietary fat-LDL-C association using prospective 
recruitment by genotype. A study reported a significant effect of Apo E genotype on the 
plasma lipid response to a low fat diet, with a 5%, 13% and 16% reduction in LDL-C in 
E3/E3, E3/E4 and E4/E4 males, respectively. Other studies have examined the association 
between Apo E genotype and fish oil (EPA/DHA) on LDL-C responses. In a retrospectively 
genotyped study it was observed that a mean increase of 7. 1% in LDL-C for the group as a 
whole was solely attributable to a 16% rise in LDL-C in the Apo E4 participants, and it was 
speculated that Apo E genotype may, in part, predict the blood lipid response to fish oil 
intervention. Variable effects of EPA and DHA on LDL-C have been reported previously 
(Kobayashi et al., 2001; Lovegrove & Gitau., 2008).  
The ApoE gene locus accounts for approximately 7% of the population variance in total and 
LDL cholesterol levels; in general, E4 carriers have higher and E2 carriers have lower LDL 
cholesterol levels. It has also been suggested that Apo E variations impact triglyceride levels, 
as higher triglyceride levels have been reported for both E4 and E2 carriers compared with 
E3 homozygotes (Rubin & Berglund, 2002).  
In a recent study of more than 9000 individuals from the Copenhagen City Heart Study, 
Frikke-Schmidt and colleagues demonstrated that the association between the Apo E locus 
and cholesterol or plasma Apo B levels was invariant, i. e. present in most contexts (e. g. 
present in both men and women), whereas associations between Apo E and other 
lipoproteins such as triglycerides, Apo A-I, HDL cholesterol and lipoprotein (a) were found 
to be context dependent (Frikke-Schmidt., 2000). As the associations of Apo E with Apo B 
remained significant when adjusting for cholesterol but not the other way around, this 
suggested that Apo B is the factor primarily associated with Apo E genotype. It should be 
pointed out, however, that in their study triglyceride levels represented nonfasting 
conditions, and LDL cholesterol was not included in the analysis (Rubin & Berglund., 2002).  
Furthermore, the Apo E2 allele was more common in individuals with high LpA-I levels,  
i. e. HDL with Apo AI but not Apo A-II. This HDL subfraction generally corresponds to the 
larger HDL2 subpopulation, which interestingly, in a study by Isasi et al, was associated 
with Apo E2 in children (Isasi et al., 2000). In view of their results, Mahley et al, suggest that 
HDL containing Apo E2 might be a poorer substrate for hepatic lipase compared with HDL 
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with Apo E3 or E4, leading to an accumulation of HDL in plasma. In addition, there might 
be a difference in the clearing mechanisms between HDL containing Apo E2 compared with 
Apo E3 or E4 (Mahley et al., 2000).  
This mixed pattern was recently addressed by Weggemans et al, who performed a meta-
analysis of 26 controlled clinical diet trials conducted. The effect of Apo E genotypes on 
response to dietary change in 395 healthy subjects, well balanced for sex, was evaluated. The 
authors pooled data in the response of LDL and HDL cholesterol from four types of trials; 
replacement of cis-unsaturated fat for saturated fat (n = 7 studies), replacement of cis-
unsaturated fat for trans unsaturated fat (n = 2), changes in dietary cholesterol (n = 8) and 
changes in coffee diterpenes (n = 9). Overall, there were small, non-significant differences 
between Apo E genotypes in the response of LDL cholesterol, and results were unchanged 
after adjusting for age, sex and body mass index. For HDL cholesterol, a sex difference was 
noted, as the response to trans fat and cholesterol differed across Apo E genotypes in men 
but not in women (Weggemans et al., 2001).  
Appropriately, the authors caution against the over interpretation of this result because of 
chance associations (Rubin & Berglund., 2002).  
Friedlander et al, compared plasma levels across Apo E genotypes in response to two diets, 
a high saturated fat/high cholesterol and a low saturated fat/low cholesterol diet, in 214 
free-living individuals in two kibbutz settlements in Israel. Although the baseline total and 
LDL cholesterol levels were higher among E4 carriers and lower among E2 carriers 
compared with E3 homozygotes, the plasma lipid response to the diet intervention did not 
differ across Apo E genotypes (Friedlander et al., 2000).  
Loktionov et al, investigated 132 free-living healthy individuals participating in the 
European Prospective Investigation of Cancer study, a cohort study with approximately 25 
000 subjects. The reported subgroup was part of a quality control study on the dietary 
methods used. In the 132 subjects, serum cholesterol levels correlated with the intake of total 
and saturated fat. For LDL cholesterol, a significant correlation with relative saturated fat 
intake was seen only for Apo E 4/3, and not for Apo E3/3 or 3/2 (Loktionov et al., 2000).  
In another recent study, researchers analyzed lipid levels in relation to Apo E genotypes in 
420 randomly selected free-living Costa Rican individuals consuming a low fat intake (53% 
of energy). In accordance with most previous studies, E2 carriers had lower, and E4 carriers 
higher LDL cholesterol and Apo B levels compared with E3 homozygotes. The population 
was dichotomized in two groups depending on the intake of saturated fat. High saturated 
fat intake (mean intake 13. 5% of energy) was associated with increased VLDL cholesterol, 
decreased HDL cholesterol and smaller LDL sizes in Apo E2 carriers, whereas the opposite 
was found for Apo E4 carriers. Effects on LDL size had previously been noted by Dreon et 
al, in which a more pronounced decrease in large, buoyant LDL particles during reduced fat 
intake was seen for Apo E4 carriers (Dreon et al, 1995). The findings of Campos et al 
suggested, as pointed out by the authors, that in E2 carriers, a high saturated fat intake may 
result in increased VLDL production and delayed clearance. Such a metabolic challenge 
might thus unmask a relative susceptibility in E2 carriers (Campos et al, 2001).  
Finally, the study on plasma lipid response to dietary fat and carbohydrate in men and 
women with coronary heart disease provided further support for the association of 
triglyceride metabolism with Apo E2. Overall, E2 carriers had lower LDL cholesterol as well 
as a tendency to higher triglyceride levels than E3 and E4 carriers. In addition, there was a 
positive association between dietary sucrose (6±7% of the total energy intake) and plasma 
triglyceride levels among E2 carriers (Rubin & Berglund., 2002).  
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Postprandial studies as Apo E have important functions in chylomicron remnant 
metabolism, there has been substantial interest in the role of Apo E genotypes in the 
postprandial setting. Furthermore, a postprandial challenge could serve as a tool to uncover 
more precisely the differences between different Apo E alleles (Rubin & Berglund., 2002).  
In a study of normolipidemic adults by Rubin & Berglund, the Apo E2 allele was associated 
with an increased postprandial triglyceride response. A similar response has also been 
demonstrated in other studies. Regarding the Apo E4 allele, more controversial results have 
been obtained (Rubin & Berglund., 2002).  
However, although such studies are compatible with a faster clearance of VLDL and 
chylomicron remnants in E4 compared with E3 carriers, the meta-analysis showed higher 
triglyceride and lower HDL cholesterol levels among E4/3 individuals compared with E3 
homozygotes. This would perhaps suggest an impaired postprandial clearance among E4 
carriers (Rubin & Berglund., 2002). In support of this, another study found an impaired 
clearance of chylomicron and VLDL remnants in normolipidemic male E4 carriers compared 
with E3/3. Furthermore, several recent studies have also reported an increased postprandial 
triglyceride excursion in E4 carriers. In children, they did not observe any difference in 
triglyceride or retinyl palmitate response between E3/3 and E4 carriers, although a non-
significant trend towards higher baseline triglyceride levels as well as higher triglyceride 
and retinyl palmitate levels 3 h postprandially among E4 carriers was seen (Couch et al., 
2000). Another research found no significant effects of the Apo E4 allele on the postprandial 
triglyceride response after adjusting for baseline triglyceride levels, although a delayed 
retinyl palmitate clearance in E2 carriers was observed (Rubin & Berglund., 2002). In a 
recent study by Kobayashi et al, individuals with the E3/3 and E3/4 genotypes were 
matched for intra-abdominal visceral fat accumulation. Postprandial triglyceride levels did 
not differ between the two genotypes when adjusting for baseline levels, whereas retinyl 
palmitate levels among lipoproteins with Sf 5400 were higher among male E3/4 subjects, 
indicating a slower remnant clearance. As pointed out by the authors, there were fewer 
women in the study, which might contribute to the non-significant finding in this sex group 
(Kobayashi et al., 2001).  
In a study, the researchers investigated postprandial fat load tolerance in 55 healthy 
volunteers with an atherogenic lipid profile, defined as triglyceride levels of 1. 5±4 m M, 
cholesterol 5±8 m M and HDL cholesterol less than 1. 1 m M, as part of a double-blind 
placebo-controlled crossover study with the consumption of either 6 g of fish oil or 6 g of 
olive oil supplements for 6 weeks. At the end of each period, a postprandial study was 
carried out. The difference in LDL cholesterol levels among Apo E genotypes is associated 
with differences in LDL receptor activity, with Apo E2 carriers having higher and Apo E4 
carriers lower activity compared with Apo E3 homozygotes. Conditions with increased 
stress of this system, such as the increased intake of cholesterol and saturated fat, could 
therefore result in a variable response in LDL cholesterol levels across Apo E genotypes. In 
addition, E2 carriers may have decreased lipolytic function with an inhibition of the 
conversion of VLDL to LDL, as well as a compromised clearance system for triglyceride-rich 
lipoproteins. Therefore, even a modestly increased VLDL production in response to 
increased precursor availability might result in differences in plasma triglyceride levels 
across Apo E genotypes (Rubin & Berglund., 2002).  
Although the results from postprandial studies are generally in agreement with the 
established metabolic differences between Apo E2 and E3, it is currently more difficult to 
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explain the reduced postprandial clearance in E4 carriers. However, it is possible that a 
differential distribution of the varying Apo E isoforms over different lipoprotein fractions, 
as well as variations in Apo E levels, could play a role. In addition, a lower LDL receptor 
activity in E4 carriers may contribute to a decreased postprandial clearance (Rubin & 
Berglund., 2002).  
How could we reconcile these varying results? Even if most studies have established 
associations between Apo E and baseline lipoprotein levels, the absolute differences 
between the Apo E genotypes are relatively modest. It might thus be expected that inter-
genotype differences in response to nutrient variations may generally be even smaller in 
magnitude, and thus more difficult to detect, although they might be enhanced by metabolic 
challenges affecting the synthetic or clearance systems in lipoprotein metabolism described 
above. Examples of such metabolic stresses in which Apo E gene nutrient interactions may 
be more readily detectable may be hyperlipidemia, an increased intake of saturated fat or 
cholesterol, the postprandial state, or alcohol intake. In agreement with this, studies 
indicating Apo E gene nutrient interactions have been more common in hyperlipidemic 
settings, whereas it has been more difficult to detect differences across Apo E genotypes in 
normolipidemic individuals or populations. However, Apo E gene± nutrient interaction has 
not been seen in all hyperlipidemic states. In familial heperlipidemia heterozygotes, no 
difference in plasma lipid response to a step 1 diet was seen across Apo E genotypes, 
indicating that the modulating effects of Apo E may be overwhelmed by other genetic 
defects, such as LDL receptor deficiency (Rubin & Berglund., 2002).  
In conclusion, Apo E has important functions in lipoprotein metabolism and the Apo E 
polymorphism is associated with plasma lipoprotein levels. Although a large number of 
studies have addressed whether there is an interaction between Apo E genotypes and diet in 
affecting plasma lipid levels, this issue is presently unresolved. Most studies to date have 
involved a small number of subjects, analyzed the Apo E polymorphism post hoc, or 
included populations in which the effects might be modest, making discrepancies difficult 
to detect. Studies conducted with conditions representing a metabolic challenge have 
generally been more successful in finding differential effects across Apo E genotypes, and 
such studies may be helpful in the future to clarify Apo E gene nutrient relationships. The 
mixed results obtained indicate that, at present, it is premature to suggest the use of 
genotyping of Apo E in the design of therapeutic diet interventions (Rubin & Berglund., 
2002).  
All studies have demonstrated a strong association between plasma cholesterol and Apo E 
phenotypes in the following order: E4/E4 > E4/E3 > E3/E3 > E3/E2. It has been thought 
possible that the Apo E gene might be involved in the modulation of dietary plasma 
cholesterol responses, perhaps explaining the differences in cholesterol concentrations. 
Some dietary intervention studies have suggested that Apo E4 individuals react to dietary 
change with exaggerated cholesterol responses. In one study, Apo E4/E4 individuals 
responded by increased cholesterol reductions during low fat intake, and by increased 
cholesterol elevations during a switchback to high fat diet. Plausible mechanisms have been 
postulated which could explain such differences. However, other studies have reported no 
differences in plasma lipid responses among Apo E phenotypes. The studies cannot be 
directly compared because of different designs and study populations with differing Apo E 
allele frequencies (Tikkanen., 1995).  
Although Tikkanen et al, found that subjects with the E4/4 phenotype showed the greatest 
total and LDL-cholesterol responses to dietary change (Tikkanen et al., 1995) Xu et al 
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analyzed the same data and concluded that the Apo E polymorphism did not explain a 
significant proportion of the variation of the response (Xu et al., 1990). In a meta-analysis of 
9 studies involving 612 subjects and found that the presence of the E4 allele was associated 
with a significantly greater LDL response to dietary intervention (Masson et al, 2003).  
Four studies found significantly different HDL-cholesterol responses between genotype 
groups: one study found that carriers of the E4 allele had the smallest HDL-cholesterol 
response, whereas the other 3 studies found that carriers of the E4 allele had the largest 
response (Masson et al., 2003).  
However, recent evidence strongly suggests that variations in a number of key genes may 
also be important, including common variants of the Apo E gene. The most convincing 
evidence to date for genotypic effects on dietary response comes from the extensively 
studied Apo E gene variant (Lovegrove & Gitau., 2008).  
5.5 Cholesteryl ester transfer protein (CETP) 
Another gene that affects HDL levels is CETP, encoding for the cholesteryl ester transfer 
protein that exchanges cholesteryl esters and triglycerids from HDL to other lipoproteins. 
This protein is also called the "lipid transfer protein:' People with two copies of a common 
allele at position 279 of this gene tend to have low HDL levels and elevated levels of LDL 
and VLDL. A variation (279G>A) that decreases plasma levels of CETP is associated with 
increased HDL levels, decreased LDL and VLDL levels, and a lower risk of cardiovascular 
disease than the more common (GG) form (DeBusk, 2009; Musunuru., 2010).  
A recent meta-analysis which confirms that the I405V and TaqIB variants are indeed 
associated with lower CETP activity and higher high-density lipoprotein-cholesterol levels 
(Boekholdt., 2004).  
The currently available evidence suggests that several genetic variants in the CETP gene are 
associated with altered CETP plasma levels and activity, high-density lipoprotein-
cholesterol plasma levels, low-density lipoprotein and high-density lipoprotein particle size, 
and perhaps the risk of coronary heart disease (Boekholdt., 2004).  
5.6 Hepatic lipase (LIPC) 
Hepatic lipase (HL) is a lipolytic enzyme involved in the hydrolysis of triacylglycerols 
present in circulating chylomicrons providing nonesterified fatty acids and 2-
monoacylglycerol for tissue utilization and phospholipids from plasma lipoproteins that 
participates in metabolizing intermediate-density lipoprotein and large LDL into smaller, 
denser LDL particles, and in converting HDL2 to HDL3 during reverse cholesterol transport 
(Ordovas & Corella., 2004; Fisler, Warden, 2005; Ordovas., 2006; Much et al., 2005). It may 
suggest a role to play as a ligand for cell-surface proteoglycans in the uptake of lipoproteins 
by cell-surface receptors (Fisler & Warden., 2005; Ordovas & Corella., 2004).  
Given the wide spectrum of effects that HL exerts on lipoprotein metabolism, and the 
significance of the promoter variant (s), it is reasonable to hypothesize that genetic variation 
at this locus may also be involved in variability in the response to dietary therapy (Ordovas 
& Corella., 2004). HL deficiency is characterized by mildly elevated concentrations of 
triglyceride-rich LDL and HDL particles, as well as impaired metabolism of postprandial 
triglyceride-rich lipoproteins, which may result in premature atherosclerosis. Conversely, 
increased HL activity is associated with increased small, dense LDL particles and decreased 
HDL2 concentrations, which may also result in increased CAD risk. Four common single 
www.intechopen.com
 
Nutrigenetics and Dyslipidemia 
 
61 
nucleotide polymorphisms (SNPs) on the 5_-flanking region of the HL gene (LIPC) [−763 
(A/G), −710 (T/C), −514 (C/T), and –250 (G/A)] are in total linkage disequilibrium and 
define a unique haplotype that is associated with variation in HL activity and HDL-
cholesterol levels (Fisler & Warden., 2005; Ordovas & Corella., 2004).  
The less common A-allele of the SNP at position−250 is associated with lower HL activity 
and buoyant LDL particles. Normal and CAD subjects heterozygous for the A-allele have 
lower HL activity and significantly more buoyant LDL particles. Homozygosity for this 
allele (AA) is associated with an even lower HL activity. The A-allele is associated with 
higher HDL2-cholesterol (Ordovas & Corella., 2004).  
An early intervention study with a low-saturated-fat, low-cholesterol diet found that, 
although significant improvements in fasting lipids occurred, there was no difference in 
response between genotypes at the hepatic lipase gene (LIPC) polymorphism measured. 
However, the study of 83 subjects may not have had adequate power to detect a modest 
effect of genotype (Fisler & Warden., 2005; Masson & McNeill., 2005; Ordovas., 2006).  
Dietary information collected from Framingham Heart Study participants shows that 
subjects carrying the CC genotype react to higher contents of fat in their diets by increasing 
the concentrations of HDL-cholesterol, which could be interpreted as a “defense 
mechanism” to maintain the homeostasis of lipoprotein metabolism. Conversely, carriers of 
the TT genotype cannot compensate, and experience decreases on the HDL-cholesterol 
levels. These data could identify a segment of the population especially susceptible to diet-
induced atherosclerosis. Considering the higher frequency of the T allele among certain 
ethnic groups (i. e., African-Americans), these data could shed some light on the impaired 
ability of certain ethnic groups to adapt to new nutritional environments, as clearly seen for 
Native Americans and Asian Indians. In this regard, they replicated the significant gene-diet 
interaction demonstrated in the Caucasian population of Framingham in another 
multiethnic cohort that consisted of Chinese, Malays, and Indians representing the 
population of Singapore. In addition to the significant gene-diet interactions reported in 
these papers, these data provides clues about the reasons why genotype-phenotype 
association studies fail to show consistent results. In theory, this polymorphism at the 
hepatic lipase gene will show dramatically different outcomes in association studies 
depending on the dietary environment of the population studies. The impact of these 
interactions will be magnified in populations with a high prevalence of the T-allele, as it is 
with Asians and African-Americans (Ordovas & Corella., 2004).  
Three larger observational studies on the effect of a common polymorphism in the LIPC 
promoter gene –514C→T on the response of HDL cholesterol to dietary fat intake have been 
published. In examining the effects of the –514C→T LIPC polymorphism x dietary fat 
interaction on HDL in 2130 men and women participating in the Framingham Study, 
Ordovas et al found that the rarer TT genotype was associated with significantly higher 
HDL-cholesterol concentrations only in subjects consuming <30% of energy from fat. This 
same interaction was found for saturated and monounsaturated fats but not for 
polyunsaturated fat. A second association study, in an Asian population of 2170 subjects, 
found that Asian Indian subjects with a total fat intake of <30% of energy and with TT 
genotype at the –514C→T polymorphism had the highest HDL-cholesterol concentrations. 
This interaction, however, did not apply to the Chinese or Malay subjects in that study, and 
the significant interactions found for saturated or monounsaturated fats found by Ordovas 
et al were not found in the study by Tai et al. However, these 2 studies are consistent with 
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other studies showing that the TT genotype at –514C→T is associated with higher HDL 
concentrations, although, in 1 of those studies, this effect was attenuated by visceral obesity 
(Fisler & Warden., 2005).  
The third association study of the interaction between dietary fat and the –514C→T 
polymorphism, by Zhang et al that, from a study population of 18159 men, Zhang et al 
selected 780 men with confirmed type 2 diabetes. After adjustment for age, smoking, alcohol 
intake, exercise, and BMI, higher HDL-cholesterol concentrations were found in men with 
the CT or TT genotype, which is consistent with previous studies. However, they found 
significantly higher HDL-cholesterol concentrations in men with the CT/TT genotype who 
consumed large amounts of dietary fat (≥32% of energy), saturated fat, and 
monounsaturated fat, a result that is apparently opposite to the findings of the other 2 
association studies. Thus, the interaction effect of dietary fat with the –514C→T 
polymorphism was not replicated (Zhang et al., 2005).  
Two researcher discussed causes of nonreplication of genetic association studies in obesity 
and diabetes research that should apply to studies of dyslipidemias as well. An important 
cause of nonreplication is a lack of statistical power. For any polygenic model, such as 
models with complex phenotypes (eg, obesity, dyslipidemia, or type 2 diabetes), the effect 
size for any marker will be small to moderate. Thus, larger sample sizes are needed to 
ensure adequate power to observe an effect. In the study of Zhang et al, the problem of 
small sample size (despite the fact that >18000 men were screened to identify ≈800 men with 
type 2 diabetes) is compounded by the fact that the TT genotype is rare, especially in a white 
population. Thus, only 30 subjects in that study had homozygous TT genotype at –514C→T 
LIPC, and subjects with either the CT or TT genotype were pooled for analysis. Examination 
of the data of Ordovas et al and Tai et al found that the slope of predicted values for HDL 
cholesterol versus total fat intake as a percentage of energy is steeply negative in persons 
with the TT genotype, whereas it is positive for persons with the CT genotype (Ordovas, et 
al, 2002; Tai et al, 2003). Assuming that the data of Zhang et al followed the same pattern, 
combining the smaller number (n = 30) of persons with the TT genotype with the larger 
number (n = 247) of persons with the CT genotype would mask the effects of percentage of 
dietary fat and the TT genotype on HDL-cholesterol concentrations. An additional 
complexity is that BMI and obesity phenotypes may also interact with dietary fat and LIPC 
genotype to modulate HDL-cholesterol concentrations (Tai et al., 2003; Zhang., 2005). Thus, 
the nonreplication in the study by Zhang et al of the findings of Ordovas et al and Tai et al is 
likely due to the small number of persons with the TT genotype who were available in the 
study of Zhang et al (Fisler & Warden., 2005).  
5.7 Lipoprotein lipase (LPL)  
LPL, encoding lipoprotein lipase, which hydrolyzes triglycerides in chylomicrons and VLDL 
particles, converting the latter to LDL particles, as well facilitating cellular lipoprotein 
uptake (Musunuru, 2010).  
Several polymorphisms have been described that disrupt normal LPL function and 
contribute to the premature development of CHD, primarily through the increased levels of 
circulating TGs (Much et al., 2005).  
Indeed, several of the common LPL polymorphisms described by Merkel et al have recently 
been established to influence circulating lipid levels in pregnant women, whom are often 
characterized with high levels of circulating TGs and increased total cholesterol (Merkel et 
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al., 2011). Although TG levels were unaffected, certain LPL SNPs modulated HDL levels and 
may alter the susceptibility of pregnant women to developing CHD. However, further 
studies are required to definitively define a relationship between lipid levels, CHD, and 
pregnant women. Therefore, the importance of LPL in the whole-body regulation of lipid 
metabolism has been avidly demonstrated and merits further exploration.  
One common LPL polymorphism, known as T495G Hind III, has been extensively examined 
and demonstrates the complexity of disease prediction associated with a single SNP. Indeed, 
preliminary indications suggest that this polymorphism may play a role in the onset of 
several important diseases, such as CHD, diabetes and obesity. This SNP has been 
associated with the higher plasma TG and lower HDL levels characteristic with the early 
onset of diabetes. Preliminary results have also suggested a positive association between the 
Hind III polymorphism and a predisposition to developing obesity. Finally, this 
polymorphism has been associated with variations in lipid levels and heart disease, and that 
these alterations were attenuated by such environmental factors as physical exercise and 
low calorie diets, reiterating the important interactions arising between lifestyle, nutrition, 
and disease. Although these associations are not conclusive, they do suggest that LPL 
variants play a critically important role in the regulation of whole-body lipid metabolism 
that may predispose an individual to the onset of several metabolic diseases.  
A relationship was established between a low calorie diet and the circulating lipid profile in 
obese individuals with the Hind III polymorphism. Homozygotes (H2H2) were found to 
have significantly higher levels of plasma VLDL-TG and Apo B than heterozygotes. Caloric 
restriction reduced lipid levels in both H2H2 and H1 individuals to a point where no 
difference was observed between the groups. Although H2H2 individuals responded more 
strongly (larger decreases in plasma lipids) to the low calorie diet, these preliminary results 
identify an important relationship between LPL polymorphisms, function, and diet (Much 
et al., 2005).  
As such, it is difficult to draw any firm conclusions from any one gene-diet study in the 
absence of replication by another study that examined the same question using similar 
methodologies. For example, one study demonstrated that a Mediterranean-style, MUFA-
rich diet compared to a high-carbohydrate diet increased LDL size in individuals with 
certain Apo E gene variants but decreased LDL size in those with other Apo E variants; this 
is potentially a clinically important observation, but no confirmatory study has yet emerged, 
calling this observation into doubt. As pointed out by others, the field would greatly benefit 
from increased collaboration and coordination of studies among international nutrition 
researchers (Musunuru., 2010).  
6. Magnitude of the response 
Because of the heterogeneity in the type and duration of the interventions described the 
magnitude of the lipid response to dietary interventions varied widely: in one study the 
change in LDL cholesterol in the Apo B EcoRI R-R- genotype group was as large as 59% of 
the baseline concentration. In the studies that showed a significant difference in response 
between genotype groups, the results also varied widely: in some studies, the difference in 
response between 2 genotype groups was ≈20% of the baseline lipid concentration (Rantala 
et al., 2000; Clitfon., 1997). However, the magnitude of these differences cannot be estimated 
with any accuracy, largely because most studies had only a small number of subjects in the 
rare genotype group (Masson et al, 2003). The proportion of variance in the lipid response 
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attributable to a single polymorphism is not likely to be > 10% (Xu et sal., 1990). Therefore, 
individual genes contribute only a small part to the variation in the lipid response; however, 
when several genes are considered, the proportion of variance explained could be larger 
(Masson et al, 2003).  
7. Evidence for a gene-diet interaction 
Evidence suggests that variation in the genes for apolipoproteins A-I, A-IV, B, and E may 
contribute to the heterogeneity in the lipid response to dietary intervention. Many studies 
were unable to show significantly different responses between these genotype groups, and 
the genotypes showing the greatest response are not necessarily consistent between studies. 
There was insufficient evidence to assess whether lipid responsiveness is affected by 
variation in the genes for Apo C-III, lipoprotein lipase, hepatic lipase, the cholesteryl ester 
transfer protein. Although each of these gene products is essential in lipid metabolism, only 
a handful of studies have investigated variation in these genes, and most of these studies 
were unable to show significant gene-diet interactions (Masson et al, 2003).  
8. Publication bias 
Publication bias is a problem with any review because "studies with results that are 
significant, interesting, from large well-funded studies, or of higher quality are more likely 
to be submitted, published, or published more rapidly than work without such 
characteristics" (Sutton, 2000). Therefore, it is possible that other relevant dietary 
intervention studies with genotype information exist but were not included in this review 
because they have not been published. It is possible that the literature strategy for this 
review missed studies because the genotype analyses were not mentioned in their title, 
abstract, or subject headings (Masson et al, 2003).  
In the search for explanations for the heterogeneity in lipid responses, reviewers may tend 
to highlight studies showing significant effects of genetic variation while ignoring a large 
proportion of studies that found no such results. Studies showing nonsignificant or 
conflicting results cannot be ignored, especially because they outnumber the studies 
showing significant effects, notwithstanding the unpublished studies that could have 
nonsignificant and uninteresting results. Therefore, one has to ask the question "If genetic 
variability plays a role in the heterogeneity of lipid and lipoprotein responses to dietary 
change, why have so many studies been unable to demonstrate this with statistical 
significance?" (Masson et al, 2003).  
9. Possible reasons for conflicting results 
There are many possible reasons why studies have been unable to show statistically 
significant gene-diet interactions. First, it is highly probable that lipid responses to dietary 
change are under polygenic control, with each gene contributing a relatively small effect. 
However, most studies have attempted to find only single-gene effects (Masson et al, 2003). 
Most of the studies summarized in this review lacked sufficient statistical power to detect 
any but a very strong effect because the sample sizes were too small, particularly for 
genotypes with low frequencies of the rare allele. However, many of the studies were 
retrospective and were not designed to examine gene-diet interactions, but data were 
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reexamined after the availability of new information from genotype analyses. Therefore, it is 
perhaps not surprising that significant effects were not found in many studies because the 
numbers of individuals in each genotype group were so small. In many studies there were 
too few subjects homozygous for the rare allele to allow an analysis that would take into 
account differences in the response between heterozygote's and homozygote's. For Apo E, 
where there are 6 possible genotypes, differences in the grouping of these could also lead to 
differences in results between studies. This illustrates that meta-analyses are important 
because they can detect effects with greater power and greater precision because of their 
inflated sample size (Rantala et al., 2000; Lopez-Miranda et al., 1994). In addition, in studies 
with small sample sizes, genotype misclassification of one individual may significantly 
affect the interpretation and validity of the results. Conflicting results may also occur 
because of the different dietary protocols that were followed. The studies reviewed varied 
widely in the composition and length of the baseline and experimental diets. The dietary 
factors responsible for the changes seen in each genotype group are not clear because many 
studies modified several dietary factors, and so the dietary content in future studies should 
be tightly controlled and compliance must be strictly measured not only for cholesterol and 
the amount and type of fatty acids but also for other influential dietary components such as 
fiber and plant sterols. In addition, these studies investigated fasting lipid and lipoprotein 
concentrations; however, the effect of genetic variation may be more evident in the 
postprandial state than in the less-common fasting state). Differences in the age, sex, body 
mass index, menopausal status, dietary backgrounds, and baseline lipid values of the 
participants could also have contributed to the discrepancies between the results. For 
instance, subjects with the E4 allele tend to have higher baseline total and LDL-cholesterol 
concentrations, and so greater responses in these subjects could reflect the regression to the 
mean phenomenon. It is also possible that weight change could account for differences in 
lipid and lipoprotein changes. In addition, a significant effect may not reflect a causal 
relation but the allele may be in linkage disequilibrium with another one that does. For 
example, the base change that results in the Xba I site in the gene for Apo B does not alter 
the amino acid, and so it may be in linkage disequilibrium with another functional mutation 
(Masson et al., 2003).  
The studies varied widely in terms of the number and type of study participants, the 
composition and duration of the dietary interventions, the nutrients studied and dietary 
assessment methods used in the observational studies, and the polymorphisms analyzed - 
some of which had not been studied before with regard to the lipid response to diet (Masson 
et al., 2005).  
10. Conclusion 
Evidence suggests that genetic variation may contribute to the heterogeneity in lipid 
responsiveness. At present, the evidence is limited but suggestive and justifies the need 
for future studies with much larger sample sizes based on power calculations, with 
carefully controlled dietary interventions, and that investigate the effects of 
polymorphisms in multiple genes rather than in single genes. Investigating gene-diet 
interactions will increase our knowledge of the mechanisms involved in lipid metabolism 
and improve our understanding of the role of diet in reducing cardiovascular disease risk 
(Masson et al., 2003).  
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Future studies will have to be large in order to assess the effects of multiple polymorphisms, 
and will have to control for many factors other than diet. At present, it is premature to 
recommend the use of genotyping in the design of therapeutic diets. However, such studies 
may be useful in identifying the mechanisms by which dietary components influence lipid 
levels (Masson & McNeill., 2005).  
However, current knowledge is still very limited and so is the potential benefit of its 
application to clinical practice. Thinking needs to evolve from simple scenarios (e. g., one 
single dietary component, a single nucleotide polymorphism and risk factor) to more 
realistic situations involving multiple interactions. One of the first situations where 
personalized nutrition is likely to be beneficial is in patients with dyslipidemia who require 
special intervention with dietary treatment. This process could be more efficient if the 
recommendations were carried out based on genetic and molecular knowledge. Moreover, 
adherence to dietary advice may increase when it is supported with information based on 
nutritional genomics, and a patient believes the advice is personalized. However, a number 
of important changes in the provision of health care are needed to achieve the potential 
benefits associated with this concept, including a teamwork  
approach with greater integration among physicians, food and nutrition professionals, and 
genetic counselors (Ordovas., 2006).  
The ultimate goal of nutritional genomics is to provide sufficient knowledge to allow 
diagnosis and nutritional treatment recommendations based on an individual’s genotype. 
Defining the interaction effects of nutrients and genes on complex phenotypes will be the 
challenge of this field of nutrition research for some time to come (Fisler & Warden, 2005; 
Gregori et al, 2011; Ordovas & Corella., 2004).  
11. Ethic 
Although an increased understanding of how these and other genes influence response to 
nutrients should facilitate the progression of personalized nutrition, the ethical issues 
surrounding its routine use need careful consideration (Lovegrove & Gitau., 2008).  
The study of nutrigenetics is in its infancy. Many studies published in this area have only 
considered one SNP in a single gene, with little consideration being given to multiple 
nutrient–gene–environmental interactions. Although this is scientifically valid, and 
invaluable for the elucidation of causative mechanisms in disease, multiple gene–nutrient–
environment–gender interactions will be required for developing specific personalized 
nutritional advice. The collation of data in haplotype databases and biobanks is expensive 
and difficult to establish, but is a necessity if nutrigenetic research is to progress (Lovegrove 
& Gitau., 2008).  
Standardized protocols in nutrigenetics are not yet established, the comparison of studies is 
challenging and conclusions are often difficult to draw. As discussed previously, studies are 
often retrospective in design and thus of insufficient power to detect nutrient–gene 
associations. Prospective genotyping increases the power to resolve these associations and 
should be used whenever possible. With any research, publication bias results in positive 
associations being reported more often than negative associations. This has applied to 
nutrigentic studies and created a false impression of the level of significance of many 
nutrient–gene interactions (Lovegrove & Gitau., 2008).  
There are numerous ethical issues and unavoidable assumptions that need to be considered 
before personalized nutritional can become routine practice. First, it is important to consider 
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whether the genetic tests and personalized food products would be affordable, cost-effective 
and socially acceptable. It is also of concern that only the well educated and affluent would 
benefit. The open accessibility of genetic information to third parties has major implications 
for the availability of health insurance and increased premiums (Lovegrove, Gitau, 2008).  
Moreover, it is still unknown whether people will want to undertake genetic tests or even 
understand the concept of such technology. A survey was conducted by Cogent Research in 
2003 on 1000 Americans in which 62% of respondents reported they had never heard of 
‘nutrigenomics’. However, if specific products did arise from nutrigenomic research, those 
interviewed did express interest in an in-depth well-being assessment and also a strong 
interest in vitamins, fortified foods and natural foods. More research is required to 
determine whether individuals would want to undergo such tests, and for understanding 
the value to the individual of an increased awareness of personalized nutrition regimens. 
There is already a large gap between the existing dietary guidelines and what people 
actually eat. Knowledge of being at higher than average risk of CVD may motivate people to 
actually make positive changes to their diets. However, genetic testing could undermine 
current healthy eating messages, by implying that only those with the ‘risky gene’ need to 
eat a healthy diet. These are important unanswered questions that must be addressed if 
personalized nutritional advice is ever to become part of mainstream disease prevention and 
treatment. It may be that the interactions between genotype–phenotype and the 
environment are just too complex to be properly understood from human dietary 
intervention studies (Lovegrove, Gitau, 2008).  
There is resistance to the use and perceived effectiveness of personalized nutrition that is 
based on genomics, and whether this can offer a solution to diseases caused by a diet that is 
inappropriate for health (Canon & Leitzmann, 2005). It has been suggested that it may be 
more beneficial to use current risk factors as a basis for population screening and the 
management of CVD (McCluskey et al., 2007). There has also been dialogue on the social, 
economic and environmental causes of CVD, shifting the emphasis away from dietary 
intake to food manufacturing as being more effective in disease management (Canon & 
Leitzmann, 2005; Lovegrove & Gitau., 2008).  
Progression of knowledge in the fields of nutrient–gene interactions promises a future 
revolution in preventative health care. However, although there is increasing evidence for 
interactions between diets/nutrients, genes and environmental factors, there are 
inconsistencies in the evidence that will limit the application of nutrigenetics in diet-related 
disease in the immediate future. In addition to the need for adequately powered 
intervention studies, greater attention should be given to ethical issues, such as the public’s 
acceptance of genetic testing and the economics of this relatively new science (Lovegrove & 
Gitau., 2008).  
Ethical issues fall into a number of categories: (1) why nutrigenomics? Will it have 
important public health benefits? (2) questions about research, e. g. concerning the 
acquisition of information about individual genetic variation; (3) questions about who has 
access to this information, and its possible misuse; (4) the applications of this information in 
terms of public health policy, and the negotiation of the potential tension between the 
interests of the individual in relation to, for example, prevention of conditions such as 
obesity and allergy; (5) the appropriate ethical approach to the issues, e. g. the moral 
difference, if any, between therapy and enhancement in relation to individualised diets; 
whether the 'technological fix' is always appropriate, especially in the wider context of the 
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purported lack of public confidence in science, which has special resonance in the sphere of 
nutrition (Chadwick., 2004).  
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